Pharmacodynamic Modeling of Clarithromycin against Macrolide-Resistant [PCR-Positive mef (A) or erm (B)] Streptococcus pneumoniae Simulating Clinically Achievable Serum and Epithelial Lining Fluid Free-Drug Concentrations

MLA

George G. Zhanel, et al. “Pharmacodynamic Modeling of Clarithromycin against Macrolide-Resistant [PCR-Positive Mef (A) or Erm (B)] Streptococcus Pneumoniae Simulating Clinically Achievable Serum and Epithelial Lining Fluid Free-Drug Concentrations.” Antimicrobial Agents and Chemotherapy, vol. 46, Dec. 2002, pp. 4029–34. EBSCOhost, https://doi.org/10.1128/aac.46.12.4029-4034.2002.

APA

George G. Zhanel, Danielle Roberts, Kim Nichol, Ayman M. Noreddin, Aleksandra Wierzbowski, & Daryl J. Hoban. (2002). Pharmacodynamic Modeling of Clarithromycin against Macrolide-Resistant [PCR-Positive mef (A) or erm (B)] Streptococcus pneumoniae Simulating Clinically Achievable Serum and Epithelial Lining Fluid Free-Drug Concentrations. Antimicrobial Agents and Chemotherapy, 46, 4029–4034. https://doi.org/10.1128/aac.46.12.4029-4034.2002

Chicago

George G. Zhanel, Danielle Roberts, Kim Nichol, Ayman M. Noreddin, Aleksandra Wierzbowski, and Daryl J. Hoban. 2002. “Pharmacodynamic Modeling of Clarithromycin against Macrolide-Resistant [PCR-Positive Mef (A) or Erm (B)] Streptococcus Pneumoniae Simulating Clinically Achievable Serum and Epithelial Lining Fluid Free-Drug Concentrations.” Antimicrobial Agents and Chemotherapy 46 (December): 4029–34. doi:10.1128/aac.46.12.4029-4034.2002.